References
- Central Brain Tumour Registry of the United States. CBTRUS Statistical Report: Primary brain and central nervous system tumours diagnosed in the United States in 2004–2006. 2010.
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.
- Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, . Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10:162–70.
- Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, . Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003; 62:297–303.
- Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, . Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009; 75:156–63.
- Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, . Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068–73.
- Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722–9.
- Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9.
- Wick W, Weller M, van den BM, Stupp R. Bevacizumab and recurrent malignant gliomas: A European perspective. J Clin Oncol 2010;28:e188–9.
- Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733–40.
- Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, . Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumour progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5.
- Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906–20.
- Roth P, Wick W, Weller M. Steroids in neurooncology: Actions, indications, side-effects. Curr Opin Neurol 2010.
- Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, . Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28: 1168–74.
- Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, . Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007; 25:3357–61.